Charoen Pokphand Enterprise (Taiwan) Co (1215) Fair Value & Analysis
Consumer Defensive · TW · Market cap 34.8B TWD
Analysis
Charoen Pokphand Enterprise (Taiwan) Co (1215) currently trades at 115.00 TWD, while our model-based Fair Value estimate is 131.00 TWD — implying the stock looks roughly 13.9% undervalued today. We read business quality at 93/100 (high quality), in the Consumer Defensive sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.
About the company
Charoen Pokphand Enterprise (Taiwan) Co., Ltd. manufactures and sells animal feeds, livestock, and chicken and processed products in Taiwan. It operates through Feed Business, Meat Processing Business, Food Processing Business, and Egg Breeding Chicken Business segments. The company engages in poultry and livestock feed; wholesale of bulk materials; electric slaughter of poultry; processing of various types of cooked meat products; breeding of egg and meat chickens; and raising of chicks. It is also involved in animal feed; breeding poultry and livestock; investment in electric poultry slaughtering; and secondary meat processing. In addition, the company engages in importing and exporting business. The company was formerly known as Taiwan Pokphand Feed Co., Ltd. and changed its name to Charoen Pokphand Enterprise (Taiwan) Co., Ltd. in 1988. Charoen Pokphand Enterprise (Taiwan) Co., Ltd. was incorporated in 1977 and is based in Taipei City, Taiwan.
Open the full interactive analysis →
Similar stocks
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.